Nebicard (Nebivolol Hydrochloride)

Nebivolol Hydrochloride, the active ingredient in Nebicard, is a beta blocker presented as an oral tablet for oral use. It is used to treat elevated blood pressure and supports cardiovascular health in adult patients. GNH USA supplies Nebicard as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nebivolol is a selective β1‑adrenergic antagonist indicated for conditions affecting the cardiovascular system. - Hypertension: lowers elevated systolic and diastolic blood pressure to reduce cardiovascular risk. - Heart Failure (reduced ejection fraction): improves cardiac output and symptoms in patients with chronic heart failure. - Elderly patients with hypertension: provides effective blood pressure control with a favorable tolerability profile.

Nebivolol may cause a range of adverse reactions, most of which are mild and dose‑related.

Common Side Effects: - Headache: mild to moderate pain often occurring early in therapy. - Dizziness: sensation of light‑headedness, especially when standing. - Fatigue: generalized tiredness or reduced energy. - Nausea: occasional stomach upset or queasiness. - Bradycardia: slower than normal heart rate. - Peripheral edema: mild swelling of ankles or feet.

Serious or Rare Side Effects: - Severe bradycardia: markedly low heart rate requiring medical attention. - Symptomatic hypotension: significant drop in blood pressure causing faintness. - Heart block: conduction abnormalities that may need intervention. - Bronchospasm: airway constriction, particularly in patients with asthma. - Allergic reactions: rash, itching, or swelling of face and throat. - Hepatic dysfunction: abnormal liver enzymes indicating liver stress.

Before initiating Nebicard, clinicians should evaluate patient-specific factors and monitor for potential risks. - Cardiovascular assessment: review baseline heart rate and blood pressure. - Hepatic impairment: adjust use in patients with liver disease. - Asthma or COPD: use with caution due to possible bronchospasm. - Diabetes monitoring: observe for changes in blood glucose control. - Abrupt discontinuation: taper gradually to avoid rebound hypertension. - Store below 25°C: keep in the original pack, protect from moisture.

Nebivolol can interact with several drug classes; awareness helps prevent adverse outcomes.

Major Interactions (Avoid): - Other beta‑blockers: additive negative chronotropic effects. - Non‑dihydropyridine calcium channel blockers (e.g., verapamil, diltiazem): increased risk of bradycardia and AV block. - Strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine): may raise nebivolol plasma levels.

Moderate Interactions (Monitor Closely):\n- Diuretics: may enhance hypotensive effect. - ACE inhibitors or ARBs: combined use can lead to excessive blood pressure reduction. - NSAIDs: may blunt antihypertensive response. - Antiarrhythmic agents (e.g., amiodarone): potential for conduction disturbances.